Inventiva named Jason Campagna as president of R&D and chief medical officer, and Martine Zimmermann as EVP of regulatory affairs and quality assurance. Evolent named Dr. David Lim as chief clinical ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Experts are raising concerns about Benadryl’s ability to cross the blood-brain barrier and potential lasting impacts.

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Kenvue Inc. has announced a leadership change and the initiation of a strategic review aimed at optimizing its brand portfolio and operating model. Kirk Perry, a Kenvue board member and former ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

The stock's fall snapped a four-day winning streak.

We recently published 10 Stocks Jim Cramer Discussed As He Commented On Latest Tariffs. Kenvue Inc. (NYSE:KVUE) is one of the ...

With activist investor Starboard Value holding a seat on Kenvue’s board of directors, the consumer healthcare company is ...